These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35314352)

  • 1. Accuracy of virtual crossmatch (VXM) prediction of physical crossmatch (PXM) results of donor specific antibody (DSA) in routine pretransplant settings-a single-center experience.
    Olszowska-Zaremba N; Zagożdżon R; Gozdowska J
    Transpl Immunol; 2022 Jun; 72():101583. PubMed ID: 35314352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N; Gozdowska J; Zagożdżon R
    Transpl Immunol; 2022 Oct; 74():101672. PubMed ID: 35868613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Rapid Optimized 96-well Tray Flow Cytometric Crossmatch (Halifax-FCXM) with Luminex Single Antigen Test.
    Yoo J; Lee S; Lee HW; Lee S; Choi J; Han J; Kang H; Choi A; Hee Jang J; Oh EJ
    Hum Immunol; 2021 Apr; 82(4):302-308. PubMed ID: 33744026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical utility and thresholds of virtual and Halifaster flow crossmatches in lung transplantation.
    Hiho SJ; Levvey B; Carroll R; Nicolson I; Mihaljcic M; Diviney MB; Snell GI; Sullivan LC; Westall GP
    HLA; 2022 Jun; 99(6):580-589. PubMed ID: 35340124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified solid-phase alloantibody detection for improved crossmatch prediction.
    Wahrmann M; Hlavin G; Fischer G; Marinova L; Schwaiger E; Hörl WH; Zlabinger GJ; Körmöczi GF; König F; Böhmig GA
    Hum Immunol; 2013 Jan; 74(1):32-40. PubMed ID: 23073293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pretransplant human leukocyte antigen antibodies detected by solid-phase assay on heart transplant outcomes.
    Gandhi MJ; DeGoey SR; Bundy K; Kremers WK; Knauer R; Pereira N; Edwards B; Kushwaha S; Daly RC
    Transplant Proc; 2011 Dec; 43(10):3840-6. PubMed ID: 22172857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Physical Crossmatch and Virtual Crossmatch to Identify Preexisting Donor-Specific Human Leukocyte Antigen (HLA) Antibodies and Outcome Following Kidney Transplantation.
    Peng B; Zhuang Q; Yu M; Li J; Liu Y; Zhu L; Ming Y
    Med Sci Monit; 2019 Feb; 25():952-961. PubMed ID: 30712055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-MFI (median fluorescence intensity) pre-transplant DSA (donor specific antibodies) leading to anamnestic antibody mediated rejection in live-related donor kidney transplantation.
    Chauhan R; Tiwari AK; Aggarwal G; Gowri Suresh L; Kumar M; Bansal SB
    Transpl Immunol; 2023 Dec; 81():101931. PubMed ID: 37730185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of Luminex-Based Single Antigen Based Results With Complement-Dependent Cytotoxicity Crossmatch and Flow Cytometry Crossmatch Results: A Single-Center Experience From Istanbul.
    Oguz SR; Sinangil A; Barlas S; Ciftci HS; Ulusoy E; İzgi DK; Ogret Y; Ecder T; Akin B
    Transplant Proc; 2023 Mar; 55(2):303-308. PubMed ID: 36890054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement-dependent cytotoxicity crossmatch in solid organ transplantation: The gold standard or golden history?
    Tafulo S; Osório E; Mendes C; Liwski R
    Hum Immunol; 2024 Jan; 85(1):110734. PubMed ID: 38030522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fallacies of a purely virtual platform: Virtual plus reality versus virtual reality - A case study.
    Gnanaraj J; Doss SA; Stephen S; Pratheeba M; Daniel D
    Transpl Immunol; 2023 Dec; 81():101956. PubMed ID: 37952899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive virtual crossmatch with negative flow crossmatch results in two cases.
    Jacob EK; De Goey SR; Gandhi MJ
    Transpl Immunol; 2011 Jul; 25(1):77-81. PubMed ID: 21641997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deceased donor kidney transplantation across donor-specific antibody barriers: predictors of antibody-mediated rejection.
    Schwaiger E; Eskandary F; Kozakowski N; Bond G; Kikić Ž; Yoo D; Rasoul-Rockenschaub S; Oberbauer R; Böhmig GA
    Nephrol Dial Transplant; 2016 Aug; 31(8):1342-51. PubMed ID: 27190362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients.
    Guidicelli G; Anies G; Bachelet T; Dubois V; Moreau JF; Merville P; Couzi L; Taupin JL
    Transpl Immunol; 2013 Dec; 29(1-4):17-21. PubMed ID: 24056164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective multi-centric study to analyze pre-transplant compatibility algorithm for live-related donor kidney transplant in Indian setting: the "Delhi approach"!
    K Tiwari A; Handoo A; Choudhary M; Mehra S; Bacchas V; Yadav A; Negi A; Chopra R
    Transpl Immunol; 2021 Dec; 69():101487. PubMed ID: 34688882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Principles of Virtual Crossmatch Testing for Kidney Transplantation.
    Bhaskaran MC; Heidt S; Muthukumar T
    Kidney Int Rep; 2022 Jun; 7(6):1179-1188. PubMed ID: 35685330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtual crossmatch in kidney transplantation.
    Piazza A; Ozzella G; Poggi E; Caputo D; Manfreda A; Adorno D
    Transplant Proc; 2014 Sep; 46(7):2195-8. PubMed ID: 25242749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients.
    Zeevi A; Lunz J; Feingold B; Shullo M; Bermudez C; Teuteberg J; Webber S
    J Heart Lung Transplant; 2013 Jan; 32(1):98-105. PubMed ID: 23142561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation.
    Riethmüller S; Ferrari-Lacraz S; Müller MK; Raptis DA; Hadaya K; Rüsi B; Laube G; Schneiter G; Fehr T; Villard J
    Transplantation; 2010 Jul; 90(2):160-7. PubMed ID: 20658760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.